These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21136968)

  • 1. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays.
    van Oostrum J; Calonder C; Rechsteiner D; Ehrat M; Mestan J; Fabbro D; Voshol H
    Proteomics Clin Appl; 2009 Apr; 3(4):412-22. PubMed ID: 21136968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of kinase inhibitors using reverse phase protein arrays.
    Martiny-Baron G; Haasen D; D'Dorazio D; Voshol J; Fabbro D
    Methods Mol Biol; 2011; 785():79-107. PubMed ID: 21901595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
    Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
    Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid carcinoma.
    Nelson JM; Fry DW
    Exp Cell Res; 1997 Jun; 233(2):383-90. PubMed ID: 9194500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
    Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
    J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
    Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of the real-time RT-PCR method for investigation of small stable RNA expression level in human epidermoid carcinoma cells A431].
    Nikitina TV; Nazarova NIu; Tishchenko LI; Tuohimaa P; Sedova VM
    Tsitologiia; 2003; 45(4):392-402. PubMed ID: 14520871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of protein phosphorylations in variant A431 cells with different growth responses to epidermal growth factor.
    Buss JE; Chouvet C; Gill GN
    J Cell Physiol; 1984 Jun; 119(3):296-306. PubMed ID: 6202705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment.
    Mermelstein FH; Abidi TF; Laskin JD
    Mol Pharmacol; 1989 Dec; 36(6):848-55. PubMed ID: 2557535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
    Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
    Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.
    Hauck CR; Sieg DJ; Hsia DA; Loftus JC; Gaarde WA; Monia BP; Schlaepfer DD
    Cancer Res; 2001 Oct; 61(19):7079-90. PubMed ID: 11585739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors.
    Williams RG; Kandasamy R; Nickischer D; Trask OJ; Laethem C; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():364-89. PubMed ID: 17110203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors.
    Lin WH; Song JS; Chang TY; Chang CY; Fu YN; Yeh CL; Wu SH; Huang YW; Fang MY; Lien TW; Hsieh HP; Chao YS; Huang SF; Tsai SF; Wang LM; Hsu JT; Chen YR
    Anal Biochem; 2008 Jun; 377(1):89-94. PubMed ID: 18358823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor.
    Matsuda K; Idezawa T; You XJ; Kothari NH; Fan H; Korc M
    Cancer Res; 2002 Oct; 62(19):5611-7. PubMed ID: 12359775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM; Roztocil E; Davies MG
    J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.
    Lebakken CS; Riddle SM; Singh U; Frazee WJ; Eliason HC; Gao Y; Reichling LJ; Marks BD; Vogel KW
    J Biomol Screen; 2009 Sep; 14(8):924-35. PubMed ID: 19564447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of signal transduction pathways protects quiescent Balb/c-3T3 fibroblasts against death due to serum deprivation.
    Tamm I; Kikuchi T
    J Cell Physiol; 1991 Jul; 148(1):85-95. PubMed ID: 1713593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.